Standard Biotools Inc. (LAB) intrinsic value & 10-year financials
Standard Biotools Inc. (LAB) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 2.2% a year to $85.3M, with an average return on invested capital of -107.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.63
- Market cap
- $240.0M
- Revenue (FY2025)
- $85.3M
- Revenue growth (10-yr CAGR)
- -2.2%
- ROIC (10-yr avg)
- -107.8%
- Free cash flow (FY2025)
- -$82.6M
LAB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $85.3M | -$74.9M | -$0.20 | -$82.6M | -129.2% | -22.2% |
| FY2024 | $174.4M | -$138.9M | -$0.52 | -$151.8M | -100.5% | -155.8% |
| FY2023 | $106.3M | -$74.7M | -$0.94 | -$46.1M | -72.0% | 90.3% |
| FY2022 | $97.9M | -$190.1M | -$2.43 | -$93.2M | -118.6% | -574.1% |
| FY2021 | $130.6M | -$59.2M | -$0.78 | -$57.3M | -51.7% | -59.1% |
| FY2020 | $138.1M | -$53.0M | -$0.74 | -$28.1M | -36.9% | -40.8% |
| FY2019 | $117.2M | -$64.8M | -$0.97 | -$37.7M | -44.2% | -89.1% |
| FY2018 | $113.0M | -$59.0M | — | -$25.6M | -42.6% | -63.9% |
| FY2017 | $101.9M | -$60.5M | — | -$25.7M | -57.3% | -32.9% |
| FY2016 | $104.4M | -$76.0M | — | -$44.2M | -70.1% | -130.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
STANDARD BIOTOOLS INC. is facing top-line stagnation, with revenue contracting over the decade.
STANDARD BIOTOOLS INC. has historically struggled to out-earn its cost of capital, averaging just -25.0% ROIC.
STANDARD BIOTOOLS INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, STANDARD BIOTOOLS INC. is modeled at -2.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.70 per share.